Fundraising Fox

Stephen Rapecki

Investor

Venture Partner at Medicxi

Slough, England, United Kingdom

About

Stephen Rapecki originated the blockbuster biologic bimekizumab from discovery to approval, combining 30 years of hands-on drug discovery at Celltech/UCB with ongoing peer-reviewed immunology research and seed-stage cofounding and advising.

Invests in

BiotechDigital HealthHealthtechMedical Devices

Experience

  1. MedicxiVenture Partnercurrent2023 β€” presentLondon, England, United Kingdom
  2. UCBDirector, Experimental Therapeutics2019 β€” 2023
  3. UCBHead Of Rationally Designed NBEs2018 β€” 2023Slough, United Kingdom
  4. UCBDirector Functional Screening2017 β€” 2023Slough, United Kingdom
  5. UCBSenior Group Leader2015 β€” 2017Slough, United Kingdom
  6. UCBSenior Principle Scientist2007 β€” 2015
  7. Celltech PharmaceuticalsSenior Scientist1993 β€” 2007Slough, United Kingdom

Skills & more

Start-up Ventures3Early Stage Investment2Immunology11Drug Discovery13Cell Culture4Pharmacology7Clinical Development2Biopharmaceuticals6Biochemistry3Biomarkers2Drug Development5Molecular Biology3
+11 moreMonoclonal AntibodiesAssay DevelopmentAntibodiesLife SciencesBiotechnologyCell BiologyR&DCellPharmaceutical IndustryELISAIn Vitro

From Stephen's professional profile.

Colleagues at Medicxi

Frequently asked questions

Who is Stephen Rapecki?
Stephen Rapecki originated the blockbuster biologic bimekizumab from discovery to approval, combining 30 years of hands-on drug discovery at Celltech/UCB with ongoing peer-reviewed immunology research and seed-stage cofounding and advising.
Where does Stephen Rapecki work?
Stephen Rapecki is Venture Partner at Medicxi.
What does Stephen Rapecki invest in?
Stephen Rapecki invests in Biotech, Digital Health, Healthtech, Medical Devices.
Where did Stephen Rapecki go to school?
Stephen Rapecki studied at Kingston University (Bachelor of Science - BS, Biomedical Sciences); Lewis Boys School.

Same school

Shared employers